Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.

Journal of cancer research and clinical oncology - 1 Apr 2023

Ullas Batra, Shrinidhi Nathany, Mansi Sharma, Narayan Satya, Parveen Jain, Surender Dhanda, Joslia Jose T, Anurag Mehta

Abstract excerpt

PURPOSE: Most common EGFR mutations in NSCLC include del19 and exon 21 L858R. Approximately 10% of patients have uncommon EGFR mutations (indels, missense mutations involving G719, L861 and S768 codons, and exon 20 insertions) that do not respond to TKIs. METHODS: Of 490 EGFR mutated NSCLC samples, 60 cases harboring uncommon/compound EGFR mutations were reviewed retrospectively, and 44 were included for survival...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 35581383
DOI: 10.1007/s00432-022-04033-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.PMID 35581383Read ↗

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.Semantic proximity Read ↗

Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India.Semantic proximity Read ↗

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.Semantic proximity Read ↗

Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatmentSemantic proximity Read ↗

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.Semantic proximity Read ↗

From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysisSemantic proximity Read ↗

Spectrum of common and uncommon compound epidermal growth factor receptor mutations in non-small cell lung carcinoma: An institutional experience from tertiary care centers from Eastern India.Semantic proximity Read ↗

Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study.Semantic proximity Read ↗

Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).Semantic proximity Read ↗

Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.Semantic proximity Read ↗

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical NeedSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.